•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Theralase Provides Bladder Cancer Clinical Study Update
Theralase(R) to Present at ThinkEquity Conference
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Theralase(R) Releases Q2 2026 Financial Statements
Theralase(R) Closes C$3.6 Million Brokered Financing
Theralase(R) Announces $5 Million Brokered LIFE Offering
Theralase(R) Grants Stock Options
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Theralase(R) Lists Warrants on the TSXV
Theralase(R) Releases Q1 2026 Financial Statements
Theralase(R) Closes C$4.8 Million Offering
Theralase Technologies Inc. (TLT:CA) Q4 2025 Earnings Call Transcript
Theralase(R) Announces $4 Million Brokered LIFE Offering
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Theralase(R) Closes $CAN 2.66 Million Financing
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Already premium?